Pricing Log in Create free account

Novavax, Inc. (NVAX) vs Palvella Therapeutics, Inc. (PVLA)

Novavax, Inc. and Palvella Therapeutics, Inc. are both Biotechnology companies. Novavax, Inc. and Palvella Therapeutics, Inc. are of similar size ($1.8B and $1.8B). Palvella Therapeutics, Inc. grew revenue faster over the last twelve months: 146.7% against −61.6%. Palvella Therapeutics, Inc. has the higher net margin (0.00% vs −59.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Novavax, Inc. leads on 8 and Palvella Therapeutics, Inc. on 8.

Valuation

Metric NVAX PVLA Biotechnology median
P/E n/m n/m 8.58
P/S 3.98 43.43 10.29
P/B n/m 8.32 2.29
Price to free cash flow n/m n/m 21.93
EV/EBITDA n/m n/m 0.67
EV/Sales 2.95 37.43 9.89
Earnings yield (15.20%) (3.84%) (31.56%)
Free cash flow yield (2.68%) (1.78%) (23.42%)

Profitability

Metric NVAX PVLA Biotechnology median
Gross margin 78.60% 100.00% 65.77%
Operating margin (56.58%) 0.00% 0.00%
Net margin (59.87%) 0.00% 0.00%
Free cash flow margin (10.20%) 0.00% 0.00%
Return on equity 323.66% (46.63%) (54.09%)
Return on assets (21.62%) (37.70%) (47.78%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NVAX PVLA Biotechnology median
Revenue growth (TTM) (61.64%) 146.67% 5.83%
EPS growth (last fiscal year) 309.76% 52.62% 29.36%
Revenue growth, 5-year CAGR 18.76% 8.03% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NVAX PVLA Biotechnology median
Debt to equity (1.54) 0.00 0.00
Current ratio 2.33 21.18 4.80
Net debt to EBITDA (1.04) 1.50 0.97

Dividend

Metric NVAX PVLA Biotechnology median
Dividend yield — — 0.44%
Payout ratio — — —

Size

Metric NVAX PVLA Biotechnology median
Market cap 1.82b 1.82b 153.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack